Merck Completes Acquisition of Themis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Mizuho Securities Reiterates Buy Rating on Merck (MRK)
June 23, 2020 6:55 AM EDTMizuho Securities analyst Mara Goldstein reiterated a Buy rating and $100.00 price target on Merck (NYSE: MRK) after KEYTRUDA is approved in China for 2L esophageal squamous cell carcinoma (ESCC) in PD-L1 positive tumors. This marks the fifth approved indication across three tumor... More
